Robert Higham

475 total citations
31 papers, 114 citations indexed

About

Robert Higham is a scholar working on Dermatology, Immunology and Physiology. According to data from OpenAlex, Robert Higham has authored 31 papers receiving a total of 114 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Dermatology, 15 papers in Immunology and 8 papers in Physiology. Recurrent topics in Robert Higham's work include Dermatology and Skin Diseases (18 papers), Psoriasis: Treatment and Pathogenesis (14 papers) and Asthma and respiratory diseases (8 papers). Robert Higham is often cited by papers focused on Dermatology and Skin Diseases (18 papers), Psoriasis: Treatment and Pathogenesis (14 papers) and Asthma and respiratory diseases (8 papers). Robert Higham collaborates with scholars based in United States, Canada and France. Robert Higham's co-authors include David R. Berk, Patrick Burnett, David W. Osborne, Archie Thurston, Melinda Gooderham, Melodie Young, Linda Stein Gold, Mark Lebwohl, Kim Papp and Laura K. Ferris and has published in prestigious journals such as Journal of the American Academy of Dermatology, British Journal of Dermatology and The Medical Journal of Australia.

In The Last Decade

Robert Higham

29 papers receiving 111 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert Higham United States	5	65	65	28	23	19	31	114
G. E. van der Kraaij Netherlands	6	62 1.0×	80 1.2×	18 0.6×	8 0.3×	16 0.8×	9	124
Joachim Koza Switzerland	4	59 0.9×	82 1.3×	20 0.7×	6 0.3×	16 0.8×	4	104
Katerina Bakirtzi Greece	6	60 0.9×	29 0.4×	10 0.4×	28 1.2×	9 0.5×	11	89
Lorne Albrecht Canada	7	102 1.6×	94 1.4×	20 0.7×	36 1.6×	34 1.8×	16	161
Federico Pirrò Italy	8	114 1.8×	157 2.4×	44 1.6×	6 0.3×	43 2.3×	11	205
Sonja Senner Germany	5	79 1.2×	27 0.4×	7 0.3×	35 1.5×	19 1.0×	6	118
N. Aszodi Germany	5	99 1.5×	25 0.4×	15 0.5×	49 2.1×	27 1.4×	7	121
Agnes Bretterklieber Austria	5	43 0.7×	61 0.9×	17 0.6×	15 0.7×	15 0.8×	5	85
Laurie Eicher Germany	4	72 1.1×	27 0.4×	6 0.2×	34 1.5×	19 1.0×	4	102
Jennifer Astrup Sørensen Denmark	8	138 2.1×	32 0.5×	28 1.0×	79 3.4×	22 1.2×	20	187

Countries citing papers authored by Robert Higham

Since Specialization

Citations

This map shows the geographic impact of Robert Higham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Higham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Higham more than expected).

Fields of papers citing papers by Robert Higham

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Higham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Higham. The network helps show where Robert Higham may publish in the future.

Co-authorship network of co-authors of Robert Higham

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Higham. A scholar is included among the top collaborators of Robert Higham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Higham. Robert Higham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Simpson, Eric L., Lawrence F. Eichenfield, Kim Papp, et al.. (2025). Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension Trial. Dermatitis. 37(1). 75–83. 1 indexed citations

Eichenfield, Lawrence F., Vimal H. Prajapati, Joseph Browning, et al.. (2025). Efficacy and Safety of Once‐Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2–5 Years With Mild‐to‐Moderate Atopic Dermatitis ( INTEGUMENT ‐ PED ): A Phase 3 Randomized Controlled Trial. Pediatric Dermatology. 42(2). 296–304. 3 indexed citations

Simpson, Eric L., Mark Boguniewicz, Lawrence F. Eichenfield, et al.. (2024). 53863 Pooled efficacy, patient-reported outcomes, and safety of roflumilast cream 0.15% from the INTEGUMENT-1 and INTEGUMENT-2 phase 3 clinical trials of adults and children with atopic dermatitis. Journal of the American Academy of Dermatology. 91(3). AB281–AB281.

Greiling, Teri M., et al.. (2024). Patient Perspectives on the Prevalence and Burden of Intertriginous Psoriasis: Results from a National Survey of Adults with Psoriasis in the United States. Dermatology and Therapy. 14(7). 1839–1847. 1 indexed citations

Draelos, Zoé Kececioglu, et al.. (2024). Assessment of the Vehicle for Roflumilast Cream Compared to a Ceramide-Containing Moisturizing Cream in Mild Eczema. Journal of Drugs in Dermatology. 23(10). 834–840. 2 indexed citations

Eichenfield, Lawrence F., Mark Boguniewicz, Eric L. Simpson, et al.. (2024). 505 - Once-daily roflumilast cream 0.15% for atopic dermatitis: pooled results from INTEGUMENT-1/2 phase 3 trials. British Journal of Dermatology. 190(Supplement_2). ii10–ii11. 1 indexed citations

Armstrong, April W., et al.. (2024). Treatment burden and the perspectives of patients with psoriasis using topical treatments: results from a national survey of adults with psoriasis in the United States. Journal of Dermatological Treatment. 35(1). 2389174–2389174. 1 indexed citations

Eichenfield, Lawrence F., John Browning, Mercedes E. González, et al.. (2024). 639 - Efficacy and safety of once-daily roflumilast cream 0.05% in pediatric patients 2 to 5 years of age with mild to moderate atopic dermatitis (INTEGUMENT-PED): a phase 3 randomized controlled trial. British Journal of Dermatology. 191(Supplement_2). 2 indexed citations

Simpson, Eric L., Lawrence F. Eichenfield, Melinda Gooderham, et al.. (2023). 390 Efficacy and safety of roflumilast cream 0.15% in adults and children aged ≥6 years with mild to moderate atopic dermatitis in two phase 3 trials (INTEGUMENT-1 and INTEGUMENT-2). British Journal of Dermatology. 188(Supplement_3). 1 indexed citations

10.

Lebwohl, Mark, Linda Stein Gold, Melinda Gooderham, et al.. (2023). Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults With Chronic Plaque Psoriasis From a 52-Week, Phase 2 Open-Label Safety Trial. SKIN The Journal of Cutaneous Medicine. 7(2). s111–s111. 1 indexed citations

11.

Lebwohl, Mark, Linda Stein Gold, Melinda Gooderham, et al.. (2023). CO45 Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults with Chronic Plaque Psoriasis from a 52-Week, Phase 2 Open-Label Safety Trial. Value in Health. 26(6). S22–S23. 1 indexed citations

12.

Eichenfield, Lawrence F., Mark Boguniewicz, Eric L. Simpson, et al.. (2023). ONCE-DAILY ROFLUMILAST CREAM 0.15% FOR ATOPIC DERMATITIS: POOLED Results: FROM INTEGUMENT-1/2 PHASE 3 TRIALS. Annals of Allergy Asthma & Immunology. 131(5). S91–S91. 4 indexed citations

13.

Simpson, Eric L., Lawrence F. Eichenfield, Melinda Gooderham, et al.. (2023). Efficacy and Safety of Roflumilast Cream 0.15% in Adults and Children Aged ≥6 Years With Mild to Moderate Atopic Dermatitis in Two Phase 3 Trials (INTEGUMENT-1 and INTEGUMENT-2). SKIN The Journal of Cutaneous Medicine. 7(4). s220–s220. 1 indexed citations

14.

Draelos, Zoe, David N. Adam, Hwanhee Hong, et al.. (2023). Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial. British Journal of Dermatology. 188(6). 810–812. 4 indexed citations

15.

Simpson, Eric L., Lawrence F. Eichenfield, Melinda Gooderham, et al.. (2023). CO136 Efficacy and Safety of Roflumilast Cream 0.15% in Adults and Children Aged 6 and Older with Mild to Moderate Atopic Dermatitis in Two Phase 3 Integument Trials. Value in Health. 26(6). S40–S40. 1 indexed citations

16.

Gold, Linda Stein, Javier Alonso‐Llamazares, Zoe Draelos, et al.. (2022). Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial. American Journal of Clinical Dermatology. 24(2). 305–313. 9 indexed citations

17.

Thurston, Archie, et al.. (2022). Pharmacokinetics of Roflumilast Cream in Chronic Plaque Psoriasis: Data from Phase I to Phase III Studies. American Journal of Clinical Dermatology. 24(2). 315–324. 20 indexed citations

18.

Gold, Linda Stein, Jerry Bagel, J.Q. Del Rosso, et al.. (2022). 33463 Pooled efficacy and safety results from the DERMIS-1 and DERMIS-2 phase 3 trials of once-daily roflumilast cream 0.3% by baseline body surface area. Journal of the American Academy of Dermatology. 87(3). AB192–AB192.

19.

Gooderham, Melinda, Javier Alonso‐Llamazares, Jerry Bagel, et al.. (2021). Roflumilast Cream 0.3% Improved the Severity and Impact of Itch in Patients With Chronic Plaque Psoriasis in the Phase 3 DERMIS-1 and DERMIS-2 Studies. SKIN The Journal of Cutaneous Medicine. 5(6). s41–s41. 3 indexed citations

20.

Young, Melodie, et al.. (2010). Managing inflammatory arthritides: Role of the nurse practitioner and physician assistant. Journal of the American Academy of Nurse Practitioners. 22(7). 382–392. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact